![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders.
Lead Product(s): ATH-399A
Therapeutic Area: Neurology Product Name: ATH-399A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hanall Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2023